Advertisement

Advertisement

TCRT Stock Latest News

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

The FlyAlaunos Therapeutics reports metabolic improvements with ALN1003 in studies

Alaunos Reports Positive Preclinical Metabolic Data for ALN1003

PremiumCompany Announcements

Alaunos Reports Positive Preclinical Metabolic Data for ALN1003

16d ago

Alaunos Highlights New Preclinical Data for Obesity Therapy

PremiumCompany Announcements

Alaunos Highlights New Preclinical Data for Obesity Therapy

25d ago

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

PremiumThe Fly

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

25d ago

Valion Bio names Melinda Lackey as General Counsel

PremiumThe Fly

Valion Bio names Melinda Lackey as General Counsel

1M ago

Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk

PremiumCompany AnnouncementsAlaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk

2M ago

Alaunos Reports Positive Preclinical Data for Obesity Candidate

Company Announcements

Alaunos Reports Positive Preclinical Data for Obesity Candidate

3M ago

Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003

The Fly

Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003

3M ago

Alaunos Updates Governance, Ends Cantor Advisory Agreement

PremiumCompany Announcements

Alaunos Updates Governance, Ends Cantor Advisory Agreement

5M ago

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

PremiumCompany Announcements

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

6M ago

Alaunos Therapeutics files to sell 327,740 shares of common for holders

PremiumThe Fly

Alaunos Therapeutics files to sell 327,740 shares of common for holders

8M ago

Alaunos Therapeutics files $50M mixed securities shelf

PremiumThe Fly

Alaunos Therapeutics files $50M mixed securities shelf

10M ago

Alaunos Therapeutics Regains Nasdaq Compliance

PremiumCompany AnnouncementsAlaunos Therapeutics Regains Nasdaq Compliance

10M ago

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

Company Announcements

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

10M ago

Alaunos Therapeutics’ Pediatric Brain Tumor Study Update: Implications and Insights

Company Announcements

Alaunos Therapeutics’ Pediatric Brain Tumor Study Update: Implications and Insights

10M ago

Alaunos Therapeutics’ TCR-T Cell Study: Long-Term Impact on Cancer Treatment

PremiumCompany Announcements

Alaunos Therapeutics’ TCR-T Cell Study: Long-Term Impact on Cancer Treatment

11M ago

Alaunos Therapeutics’ TCR-T Study Update: Implications for Investors

PremiumCompany Announcements

Alaunos Therapeutics’ TCR-T Study Update: Implications for Investors

11M ago

Alaunos Therapeutics Announces Departure of Melinda Lackey

PremiumCompany Announcements

Alaunos Therapeutics Announces Departure of Melinda Lackey

11M ago

Alaunos Therapeutics Holds Annual Stockholders Meeting

PremiumCompany Announcements

Alaunos Therapeutics Holds Annual Stockholders Meeting

11M ago

Alaunos Therapeutics Appoints Holger Weis as New CEO

PremiumCompany AnnouncementsAlaunos Therapeutics Appoints Holger Weis as New CEO

11M ago

Alaunos Therapeutics Raises $850,000 in Private Offering

Company Announcements

Alaunos Therapeutics Raises $850,000 in Private Offering

12M ago

Alaunos Therapeutics Closes Registered Direct Offering

Company Announcements

Alaunos Therapeutics Closes Registered Direct Offering

12M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >